Stablepoint Partners LLC Has $1.98 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Stablepoint Partners LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,798 shares of the medical research company’s stock after selling 135 shares during the quarter. Stablepoint Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,976,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Novare Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 2.1% in the 4th quarter. Novare Capital Management LLC now owns 23,515 shares of the medical research company’s stock worth $12,233,000 after acquiring an additional 490 shares during the period. Clarendon Private LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $440,000. Regency Capital Management Inc. DE bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $3,701,000. Archford Capital Strategies LLC lifted its position in shares of Thermo Fisher Scientific by 2.0% during the 4th quarter. Archford Capital Strategies LLC now owns 4,101 shares of the medical research company’s stock worth $2,134,000 after buying an additional 80 shares during the period. Finally, AlphaMark Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 3.2% during the fourth quarter. AlphaMark Advisors LLC now owns 2,308 shares of the medical research company’s stock worth $1,201,000 after purchasing an additional 72 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research reports. TD Cowen lifted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, January 14th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Stephens began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock. Finally, Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the completion of the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. The trade was a 7.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 44,850 shares of company stock valued at $24,666,097 in the last ninety days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $575.21 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The stock has a fifty day simple moving average of $533.60 and a 200 day simple moving average of $569.32. The company has a market capitalization of $220.02 billion, a price-to-earnings ratio of 36.06, a PEG ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the firm posted $5.69 earnings per share. The business’s revenue was up .2% compared to the same quarter last year. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock repurchase plan on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.